CL2008000329A1 - Compuestos derivados de octahidro fenantreno sustituidos; composicion farmaceutica que comprende a dichos compuestos; y su uso para tratar asma, dermatitis, enfermedad de alzheimer, depresion, enfermedad pulmonar, entre otras enfermedades. - Google Patents

Compuestos derivados de octahidro fenantreno sustituidos; composicion farmaceutica que comprende a dichos compuestos; y su uso para tratar asma, dermatitis, enfermedad de alzheimer, depresion, enfermedad pulmonar, entre otras enfermedades.

Info

Publication number: CL2008000329A1
Authority: CL; Chile
Prior art keywords: compounds; disease; fenantreno; octahidro; dermatitis
Prior art date: 2007-02-02

Application number

CL200800329A

Other languages

English (en)

Inventor

Cheng Xiao Hu Kevin D Hengmiao

Original Assignee

Pfizer Products Inc Sa Organiz

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

2007-02-02

Filing date

2008-02-01

Publication date

2008-08-08

2008-02-01 Application filed by Pfizer Products Inc Sa Organiz filed Critical Pfizer Products Inc Sa Organiz

2008-08-08 Publication of CL2008000329A1 publication Critical patent/CL2008000329A1/es

Classifications

- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
- C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
- C07D213/89—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members with hetero atoms directly attached to the ring nitrogen atom
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
- C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
- C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
- C07D213/60—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D213/72—Nitrogen atoms
- C07D213/75—Amino or imino radicals, acylated by carboxylic or carbonic acids, or by sulfur or nitrogen analogues thereof, e.g. carbamates
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/02—Stomatological preparations, e.g. drugs for caries, aphtae, periodontitis
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/18—Drugs for disorders of the alimentary tract or the digestive system for pancreatic disorders, e.g. pancreatic enzymes
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/06—Antiasthmatics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/16—Central respiratory analeptics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/12—Drugs for disorders of the urinary system of the kidneys
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/06—Antipsoriatics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/08—Antiseborrheics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/14—Drugs for dermatological disorders for baldness or alopecia
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/06—Antigout agents, e.g. antihyperuricemic or uricosuric agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
- A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P21/00—Drugs for disorders of the muscular or neuromuscular system
- A61P21/04—Drugs for disorders of the muscular or neuromuscular system for myasthenia gravis
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/02—Drugs for disorders of the nervous system for peripheral neuropathies
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
- A61P25/16—Anti-Parkinson drugs
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/24—Antidepressants
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
- A61P27/04—Artificial tears; Irrigation solutions
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
- A61P27/14—Decongestants or antiallergics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/16—Otologicals
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/04—Anorexiants; Antiobesity agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/12—Drugs for disorders of the metabolism for electrolyte homeostasis
- A61P3/14—Drugs for disorders of the metabolism for electrolyte homeostasis for calcium homeostasis
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/02—Antineoplastic agents specific for leukemia
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/08—Antiallergic agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/06—Antianaemics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/10—Antioedematous agents; Diuretics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
- C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
- C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
- C07D213/60—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D213/72—Nitrogen atoms
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
- C07F9/00—Compounds containing elements of Groups 5 or 15 of the Periodic Table
- C07F9/02—Phosphorus compounds
- C07F9/547—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom
- C07F9/553—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom having one nitrogen atom as the only ring hetero atom
- C07F9/576—Six-membered rings
- C07F9/58—Pyridine rings

Landscapes

Health & Medical Sciences (AREA)
Chemical & Material Sciences (AREA)
Organic Chemistry (AREA)
Life Sciences & Earth Sciences (AREA)
General Health & Medical Sciences (AREA)
Veterinary Medicine (AREA)
Public Health (AREA)
Medicinal Chemistry (AREA)
Animal Behavior & Ethology (AREA)
Pharmacology & Pharmacy (AREA)
Engineering & Computer Science (AREA)
Bioinformatics & Cheminformatics (AREA)
General Chemical & Material Sciences (AREA)
Chemical Kinetics & Catalysis (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
Neurology (AREA)
Biomedical Technology (AREA)
Neurosurgery (AREA)
Diabetes (AREA)
Immunology (AREA)
Physical Education & Sports Medicine (AREA)
Rheumatology (AREA)
Hematology (AREA)
Pulmonology (AREA)
Dermatology (AREA)
Orthopedic Medicine & Surgery (AREA)
Psychiatry (AREA)
Epidemiology (AREA)
Pain & Pain Management (AREA)
Obesity (AREA)
Ophthalmology & Optometry (AREA)
Biochemistry (AREA)
Molecular Biology (AREA)
Endocrinology (AREA)
Psychology (AREA)
Transplantation (AREA)
Urology & Nephrology (AREA)
Emergency Medicine (AREA)
Hospice & Palliative Care (AREA)
Child & Adolescent Psychology (AREA)

CL200800329A 2007-02-02 2008-02-01 Compuestos derivados de octahidro fenantreno sustituidos; composicion farmaceutica que comprende a dichos compuestos; y su uso para tratar asma, dermatitis, enfermedad de alzheimer, depresion, enfermedad pulmonar, entre otras enfermedades. CL2008000329A1 (es)

Applications Claiming Priority (1)

Application Number	Priority Date	Filing Date	Title
US88798107P	2007-02-02	2007-02-02

Publications (1)

Publication Number	Publication Date
CL2008000329A1 true CL2008000329A1 (es)	2008-08-08

Family

ID=39315208

Family Applications (2)

Application Number	Title	Priority Date	Filing Date
CL200800329A CL2008000329A1 (es)	2007-02-02	2008-02-01	Compuestos derivados de octahidro fenantreno sustituidos; composicion farmaceutica que comprende a dichos compuestos; y su uso para tratar asma, dermatitis, enfermedad de alzheimer, depresion, enfermedad pulmonar, entre otras enfermedades.
CL200800330A CL2008000330A1 (es)	2007-02-02	2008-02-01	Compuestos derivados de octahidro fenantreno sustituidos; composicion farmaceutica que comprende a dichos compuestos; y su uso para tratar asma, dermatitis, enfermedad de alzheimer, artritis, entre otras enfermedades.

Family Applications After (1)

Application Number	Title	Priority Date	Filing Date
CL200800330A CL2008000330A1 (es)	2007-02-02	2008-02-01	Compuestos derivados de octahidro fenantreno sustituidos; composicion farmaceutica que comprende a dichos compuestos; y su uso para tratar asma, dermatitis, enfermedad de alzheimer, artritis, entre otras enfermedades.

Country Status (42)

Country	Link
US (7)	US7598231B2 (es)
EP (1)	EP2114970B1 (es)
JP (1)	JP4599462B2 (es)
KR (2)	KR101107949B1 (es)
CN (2)	CN101616925B (es)
AP (1)	AP2455A (es)
AR (2)	AR065134A1 (es)
AT (1)	ATE518872T1 (es)
AU (1)	AU2008211613B2 (es)
BR (1)	BRPI0808634A2 (es)
CA (1)	CA2676670C (es)
CL (2)	CL2008000329A1 (es)
CO (2)	CO6220937A2 (es)
CR (2)	CR10948A (es)
CU (2)	CU23824A3 (es)
CY (2)	CY1110962T1 (es)
DK (1)	DK2114970T3 (es)
DO (1)	DOP2009000190A (es)
EA (1)	EA016494B1 (es)
EC (2)	ECSP099552A (es)
ES (2)	ES2368286T3 (es)
GE (2)	GEP20125404B (es)
GT (2)	GT200900209A (es)
HN (2)	HN2008000179A (es)
HR (1)	HRP20110702T1 (es)
IL (1)	IL199972A (es)
MA (2)	MA31117B1 (es)
MX (1)	MX2009008284A (es)
MY (3)	MY153057A (es)
NI (2)	NI200900149A (es)
NZ (1)	NZ578638A (es)
PE (2)	PE20081736A1 (es)
PL (1)	PL2114970T3 (es)
PT (2)	PT2114970E (es)
RS (2)	RS51970B (es)
SI (1)	SI2114970T1 (es)
SV (2)	SV2009003346A (es)
TN (1)	TN2009000324A1 (es)
TW (2)	TWI373466B (es)
UA (2)	UA94639C2 (es)
WO (1)	WO2008093227A1 (es)
ZA (2)	ZA200906060B (es)

Families Citing this family (24)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
JP3693258B2 (ja)	1996-07-24	2005-09-07	ワーナー―ランバート・コンパニー	イソブチルｇａｂａまたはその誘導体を含有する鎮静剤
KR101107949B1 (ko) *	2007-02-02	2012-02-08	화이자 프로덕츠 인코포레이티드	트라이사이클릭 화합물 및 글루코코르티코이드 수용체 조절자로서의 이들의 용도
MX2011001053A (es)	2008-07-28	2011-04-21	Pfizer	Compuestos de fenantrenona, composiciones y metodos.
US8765787B2 (en) *	2008-11-21	2014-07-01	Bridge Pharma, Inc.	Methods of treatment of xerophthalmia with self-preserving ocular formulations of norketotifen
US20100136096A1 (en) *	2008-12-02	2010-06-03	Searete Llc, A Limited Liability Corporation Of The State Of Delaware	Systems for modulating inflammation
US20100135983A1 (en) *	2008-12-02	2010-06-03	Searete Llc, A Limited Liability Corporation Of The State Of Delaware	Anti-inflammatory compositions and methods
US20100137246A1 (en) *	2008-12-02	2010-06-03	Searete Llc, A Limited Liability Corporation Of The State Of Delaware	Anti-inflammatory compositions and methods
US20100136094A1 (en) *	2008-12-02	2010-06-03	Searete Llc, A Limited Liability Corporation Of The State Of Delaware	Systems for modulating inflammation
US20100136097A1 (en) *	2008-12-02	2010-06-03	Searete Llc, A Limited Liability Corporation Of The State Of Delaware	Systems for modulating inflammation
US20100136095A1 (en) *	2008-12-02	2010-06-03	Searete Llc, A Limited Liability Corporation Of The State Of Delaware	Systems for modulating inflammation
US20100137787A1 (en) *	2008-12-02	2010-06-03	Searete Llc, A Limited Liability Corporation Of The State Of Delaware	Delivery devices for modulating inflammation
EP2569307A2 (en)	2010-05-10	2013-03-20	Radikal Therapeutics Inc.	Lipoic acid and nitroxide derivatives and uses thereof
BR112013004322A2 (pt) *	2010-08-27	2016-06-21	Corcept Therapeutics Inc	moduladores de azadecalin fundidos com piridil-aminas
EP2685821A4 (en) *	2011-03-15	2014-08-20	Abbvie Inc	MODULATORS OF NUCLEAR HORMONAL RECEPTORS
US8545904B1 (en)	2012-06-05	2013-10-01	Liquid Innovators, LLC	Topical composition containing Carapa (andiroba) oil for psoriasis and other related dermatological disorders
US9227901B2 (en) *	2012-07-05	2016-01-05	Abbvie Inc.	Process for preparing bicyclic amine derivatives
TW201422590A (zh)	2012-09-07	2014-06-16	Abbvie Inc	雜環核激素受體調節劑
WO2014094357A1 (en)	2012-12-21	2014-06-26	Abbvie Inc.	Heterocyclic nuclear hormone receptor modulators
KR101787310B1 (ko)	2014-05-16	2017-10-18	리퀴드 인코포레이티드	케라틴 처리 제형 및 방법
US9504645B2 (en)	2014-10-20	2016-11-29	Oyster Point Pharma, Inc.	Pharmaceutical formulations for treating ocular conditions
CN104591988A (zh) *	2014-12-29	2015-05-06	甘肃省化工研究院	6-溴-2-萘满酮的合成方法
EP4591936A3 (en)	2015-03-23	2025-10-15	Tianli Biotech Pty Ltd	Treatment of respiratory diseases
US10709707B2 (en)	2016-04-07	2020-07-14	Oyster Point Pharma, Inc.	Methods of treating ocular conditions
CN113260616B (zh)	2018-11-07	2025-05-02	天莅生物技术有限公司	用于治疗呼吸系统疾病的新型化合物

Family Cites Families (28)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
FR2576025B1 (fr)	1985-01-14	1987-01-23	Roussel Uclaf	Nouveaux steroides substitues en position 10, leur procede et les intermediaires de preparation, leur application comme medicaments, les compositions pharmaceutiques les contenant
FR2600450B1 (fr) *	1986-06-19	1988-08-26	Pechiney Aluminium	Procede de marquage individuel des anodes precuites pour la production electrolytique d'aluminium
GB9518953D0 (en)	1995-09-15	1995-11-15	Pfizer Ltd	Pharmaceutical formulations
IL122740A (en)	1997-01-15	2003-09-17	Akzo Nobel Nv	16-hydroxy-11-(substituted phenyl)-estra-9,4-diene derivatives, their preparation and pharmaceutical compositions containing them
OA11877A (en) *	1999-04-30	2006-03-29	Pfizer Prod Inc	Glucocorticoid receptor modulators.
US6544781B1 (en)	1999-07-15	2003-04-08	The General Hospital Corporation	Non-defective Epstein-Barr viral vector
IL180679A0 (en) *	2000-10-27	2009-02-11	Pfizer Prod Inc	Process for the preparation of non-steroidal glucocorticoid receptor modulators
JP2002193911A (ja) *	2000-10-28	2002-07-10	Pfizer Prod Inc	グルココルチコイドレセプターモジュレーター
ES2246292T3 (es)	2000-10-30	2006-02-16	Pfizer Products Inc.	Moduladores de receptor glucocorticoide.
DE10196880T1 (de) *	2000-11-20	2003-12-18	Seagate Technology Llc	RF-ID-Tag-Attachment an ein Plattenlaufwerk
MXPA03011935A (es)	2001-06-22	2004-03-26	Pfizer Prod Inc	Composiciones farmaceuticas que contienen conjuntos de polimero y farmaco.
NZ531477A (en)	2001-08-31	2006-10-27	Corcept Therapeutics Inc	Use of a glucocorticoid receptor antagonist comprising a steroidal skeleton with at least one phenyl-containing moiety in the 11-beta position of the steroidal skeleton to decrease cognitive deterioration in adults with Down's syndrome
AU2002337116B2 (en)	2001-09-27	2008-01-31	Universite De Liege	Pyridinic sulfonamide derivatives, method of production and use thereof
DE10164366C1 (de) *	2001-12-28	2003-06-05	Rehau Ag & Co	Permanentkathode
ES2305434T3 (es)	2002-02-01	2008-11-01	Pfizer Products Inc.	Composiciones framaceuticas de dispersiones amorfas de farmacos y materiales que forman microfases lipofilas.
WO2004004653A2 (en)	2002-07-02	2004-01-15	Corcept Therapeutics, Inc.	Methods for treating psychosis associated with interferon-alpha therapy
JP4503436B2 (ja)	2002-07-08	2010-07-14	ファイザー・プロダクツ・インク	糖質コルチコイド受容体のモジュレーター
JP2006507311A (ja)	2002-11-05	2006-03-02	コーセプトセラピューティクス，インコーポレイテッド	胃食道逆流性疾患を処置するための方法
US20040229855A1 (en)	2003-02-04	2004-11-18	Corcept Therapeutics, Inc.	Antiglucocorticoids for the treatment of postpartum psychosis
US20050080061A1 (en)	2003-07-23	2005-04-14	Corcept Therapeutics, Inc.	Antiglucocorticoid therapy for the prevention of neurological damage in premature infants
US8097606B2 (en)	2003-07-23	2012-01-17	Corcept Therapeutics, Inc.	Antiglucocorticoids for the treatment of catatonia
TW200512181A (en)	2003-09-26	2005-04-01	Tanabe Seiyaku Co	Amide-type carboxamide derivatives
EP1682150B1 (en) *	2003-11-10	2012-12-26	The Scripps Research Institute	Compositions and methods for inducing cell dedifferentiation
AU2004289532A1 (en) *	2003-11-13	2005-05-26	Pfizer Products Inc.	Octahydrophenanthrene hydrazinde derivatives useful as glucocorticoid receptor modulators
TWI370129B (en)	2005-02-14	2012-08-11	Msd Oss Bv	Non steroidal glucocorticoid receptor modulators
JP2009535430A (ja)	2006-05-02	2009-10-01	コーセプトセラピューティクス，インコーポレイテッド	Ｉｌ−２を摂取している患者における抑うつを処置するためのグルココルチコイドレセプターｉｉアンタゴニストの使用
KR101107949B1 (ko) *	2007-02-02	2012-02-08	화이자 프로덕츠 인코포레이티드	트라이사이클릭 화합물 및 글루코코르티코이드 수용체 조절자로서의 이들의 용도
WO2008093236A1 (en) *	2007-02-02	2008-08-07	Pfizer Products Inc.	Tricyclic compounds and their use as glucocorticoid receptor modulators

2008
- 2008-01-25 KR KR1020097018289A patent/KR101107949B1/ko not_active Expired - Fee Related
- 2008-01-25 ES ES08702351T patent/ES2368286T3/es active Active
- 2008-01-25 AT AT08702351T patent/ATE518872T1/de active
- 2008-01-25 BR BRPI0808634-6A patent/BRPI0808634A2/pt not_active IP Right Cessation
- 2008-01-25 DK DK08702351.1T patent/DK2114970T3/da active
- 2008-01-25 CN CN2008800052954A patent/CN101616925B/zh not_active Expired - Fee Related
- 2008-01-25 MX MX2009008284A patent/MX2009008284A/es active IP Right Grant
- 2008-01-25 HR HR20110702T patent/HRP20110702T1/hr unknown
- 2008-01-25 WO PCT/IB2008/000229 patent/WO2008093227A1/en not_active Ceased
- 2008-01-25 SI SI200830393T patent/SI2114970T1/sl unknown
- 2008-01-25 RS RS20110429A patent/RS51970B/sr unknown
- 2008-01-25 AU AU2008211613A patent/AU2008211613B2/en not_active Ceased
- 2008-01-25 UA UAA200907728A patent/UA94639C2/ru unknown
- 2008-01-25 MY MYPI20123293 patent/MY153057A/en unknown
- 2008-01-25 PT PT08702351T patent/PT2114970E/pt unknown
- 2008-01-25 EA EA200970666A patent/EA016494B1/ru not_active IP Right Cessation
- 2008-01-25 GE GEAP200811399A patent/GEP20125404B/en unknown
- 2008-01-25 PL PL08702351T patent/PL2114970T3/pl unknown
- 2008-01-25 EP EP08702351A patent/EP2114970B1/en active Active
- 2008-01-25 MY MYPI20093089A patent/MY146087A/en unknown
- 2008-01-25 JP JP2009547778A patent/JP4599462B2/ja not_active Expired - Fee Related
- 2008-01-25 AP AP2009004942A patent/AP2455A/xx active
- 2008-01-25 NZ NZ578638A patent/NZ578638A/en not_active IP Right Cessation
- 2008-01-25 CA CA2676670A patent/CA2676670C/en not_active Expired - Fee Related
- 2008-01-28 KR KR1020097018294A patent/KR101114682B1/ko not_active Expired - Fee Related
- 2008-01-28 PT PT08702358T patent/PT2114888E/pt unknown
- 2008-01-28 CN CN2008800056527A patent/CN101616896B/zh not_active Expired - Fee Related
- 2008-01-28 GE GEAP200811398A patent/GEP20125426B/en unknown
- 2008-01-28 UA UAA200907730A patent/UA95332C2/uk unknown
- 2008-01-28 MY MYPI20093135A patent/MY148780A/en unknown
- 2008-01-28 RS RS20110008A patent/RS51646B/sr unknown
- 2008-01-28 ES ES08702358T patent/ES2353822T3/es active Active
- 2008-01-31 PE PE2008000231A patent/PE20081736A1/es not_active Application Discontinuation
- 2008-01-31 US US12/023,362 patent/US7598231B2/en not_active Expired - Fee Related
- 2008-01-31 US US12/023,323 patent/US7547714B2/en not_active Expired - Fee Related
- 2008-02-01 HN HN2008000179A patent/HN2008000179A/es unknown
- 2008-02-01 PE PE2008000234A patent/PE20090113A1/es not_active Application Discontinuation
- 2008-02-01 HN HN2008000178A patent/HN2008000178A/es unknown
- 2008-02-01 TW TW097104074A patent/TWI373466B/zh not_active IP Right Cessation
- 2008-02-01 AR ARP080100424A patent/AR065134A1/es active IP Right Grant
- 2008-02-01 CL CL200800329A patent/CL2008000329A1/es unknown
- 2008-02-01 CL CL200800330A patent/CL2008000330A1/es unknown
- 2008-02-01 TW TW097104089A patent/TWI347842B/zh active
- 2008-02-01 AR ARP080100425A patent/AR065135A1/es active IP Right Grant
2009
- 2009-05-08 US US12/437,704 patent/US8158660B2/en not_active Expired - Fee Related
- 2009-07-20 IL IL199972A patent/IL199972A/en active IP Right Grant
- 2009-07-21 US US12/506,825 patent/US7786097B2/en not_active Expired - Fee Related
- 2009-07-23 CR CR10948A patent/CR10948A/es not_active IP Right Cessation
- 2009-07-23 CR CR10949A patent/CR10949A/es not_active IP Right Cessation
- 2009-07-24 CU CU20090133A patent/CU23824A3/es active IP Right Grant
- 2009-07-24 CU CU2009000132A patent/CU23848B1/es active IP Right Grant
- 2009-07-29 NI NI200900149A patent/NI200900149A/es unknown
- 2009-07-29 NI NI200900148A patent/NI200900148A/es unknown
- 2009-07-29 DO DO2009000190A patent/DOP2009000190A/es unknown
- 2009-07-30 GT GT200900209A patent/GT200900209A/es unknown
- 2009-07-30 SV SV2009003346A patent/SV2009003346A/es not_active Application Discontinuation
- 2009-07-30 GT GT200900210A patent/GT200900210A/es unknown
- 2009-07-31 CO CO09079789A patent/CO6220937A2/es active IP Right Grant
- 2009-07-31 SV SV2009003349A patent/SV2009003349A/es active IP Right Grant
- 2009-07-31 EC EC2009009552A patent/ECSP099552A/es unknown
- 2009-07-31 MA MA32127A patent/MA31117B1/fr unknown
- 2009-07-31 MA MA32128A patent/MA31158B1/fr unknown
- 2009-07-31 CO CO09079796A patent/CO6190603A2/es active IP Right Grant
- 2009-07-31 EC EC2009009553A patent/ECSP099553A/es unknown
- 2009-07-31 TN TNP2009000324A patent/TN2009000324A1/fr unknown
- 2009-09-01 ZA ZA200906060A patent/ZA200906060B/xx unknown
- 2009-09-01 ZA ZA200906064A patent/ZA200906064B/xx unknown
2010
- 2010-12-02 CY CY20101101109T patent/CY1110962T1/el unknown
2011
- 2011-08-17 CY CY20111100784T patent/CY1111758T1/el unknown
- 2011-12-21 US US13/333,104 patent/US8445520B2/en not_active Expired - Fee Related
2013
- 2013-04-16 US US13/863,534 patent/US20140142316A1/en not_active Abandoned
2014
- 2014-07-01 US US14/320,674 patent/US8901310B2/en not_active Expired - Fee Related

Also Published As

Publication number	Publication date
CR10948A (es)	2009-08-07
TWI347842B (en)	2011-09-01
CA2676670A1 (en)	2008-08-07
CN101616896A (zh)	2009-12-30
PT2114888E (pt)	2011-01-04
MY148780A (en)	2013-05-31
CA2676670C (en)	2012-03-13
CN101616896B (zh)	2012-07-04
MY146087A (en)	2012-06-29
ZA200906064B (en)	2010-05-26
HK1135108A1 (en)	2010-05-28
AP2455A (en)	2012-08-31
SV2009003346A (es)	2010-04-13
US7547714B2 (en)	2009-06-16
NI200900148A (es)	2010-02-15
US20120095062A1 (en)	2012-04-19
DOP2009000190A (es)	2009-08-31
EP2114970A1 (en)	2009-11-11
US7786097B2 (en)	2010-08-31
IL199972A0 (en)	2010-04-15
US20090281148A1 (en)	2009-11-12
US8901310B2 (en)	2014-12-02
US20140316139A1 (en)	2014-10-23
SV2009003349A (es)	2010-04-13
ES2368286T3 (es)	2011-11-16
KR101114682B1 (ko)	2012-03-14
CY1110962T1 (el)	2015-06-11
RS51970B (sr)	2012-02-29
KR20090107080A (ko)	2009-10-12
TW200838514A (en)	2008-10-01
CR10949A (es)	2009-08-07
US20080312294A1 (en)	2008-12-18
US8158660B2 (en)	2012-04-17
UA94639C2 (ru)	2011-05-25
CO6190603A2 (es)	2010-08-19
JP4599462B2 (ja)	2010-12-15
TN2009000324A1 (fr)	2010-12-31
HN2008000179A (es)	2010-06-09
ZA200906060B (en)	2010-05-26
MX2009008284A (es)	2009-08-12
HRP20110702T1 (hr)	2011-10-31
SI2114970T1 (sl)	2011-11-30
ECSP099553A (es)	2009-08-28
CU20090133A7 (es)	2011-10-31
GT200900209A (es)	2010-07-22
CU23824A3 (es)	2011-10-31
NZ578638A (en)	2010-12-24
CU20090132A7 (es)	2011-10-14
TW200846325A (en)	2008-12-01
KR20090108115A (ko)	2009-10-14
GEP20125426B (en)	2012-03-26
AR065135A1 (es)	2009-05-20
EA200970666A1 (ru)	2010-02-26
US20140142316A1 (en)	2014-05-22
RS51646B (sr)	2011-10-31
AP2009004942A0 (en)	2009-08-31
AR065134A1 (es)	2009-05-20
GEP20125404B (en)	2012-02-27
BRPI0808634A2 (pt)	2014-08-05
US20100286214A1 (en)	2010-11-11
MA31158B1 (fr)	2010-02-01
US20120088802A9 (en)	2012-04-12
CO6220937A2 (es)	2010-11-19
PE20090113A1 (es)	2009-02-13
EP2114970B1 (en)	2011-08-03
JP2010517990A (ja)	2010-05-27
NI200900149A (es)	2010-02-15
HN2008000178A (es)	2011-02-25
CU23848B1 (es)	2012-10-15
PE20081736A1 (es)	2008-11-28
TWI373466B (en)	2012-10-01
UA95332C2 (uk)	2011-07-25
ECSP099552A (es)	2009-08-28
GT200900210A (es)	2010-04-05
PT2114970E (pt)	2011-09-22
ES2353822T3 (es)	2011-03-07
KR101107949B1 (ko)	2012-02-08
ATE518872T1 (de)	2011-08-15
CY1111758T1 (el)	2015-10-07
MA31117B1 (fr)	2010-01-04
MY153057A (en)	2014-12-31
WO2008093227A1 (en)	2008-08-07
AU2008211613B2 (en)	2013-05-23
AU2008211613A1 (en)	2008-08-07
US7598231B2 (en)	2009-10-06
US20080188443A1 (en)	2008-08-07
CN101616925B (zh)	2012-05-23
IL199972A (en)	2013-09-30
CL2008000330A1 (es)	2008-08-08
CN101616925A (zh)	2009-12-30
EA016494B1 (ru)	2012-05-30
PL2114970T3 (pl)	2011-11-30
DK2114970T3 (da)	2011-09-19
US8445520B2 (en)	2013-05-21

Publication	Publication Date	Title
CL2008000329A1 (es)	2008-08-08	Compuestos derivados de octahidro fenantreno sustituidos; composicion farmaceutica que comprende a dichos compuestos; y su uso para tratar asma, dermatitis, enfermedad de alzheimer, depresion, enfermedad pulmonar, entre otras enfermedades.
CL2008000369A1 (es)	2008-04-18	Compuestos derivados de piridopirimidinonas; composicion farmaceutica que comprende a dichos compuestos; y su uso para tratar dolor, depresion, enfermedades cardiovasculares, enfermedades respiratorias y enfermedades psiquiatricas.
CL2007002791A1 (es)	2008-04-11	Compuestos derivados de sulfonamida; composicion farmaceutica que comprende a estos compuestos; combinacion farmaceutica que comprende a estos compuestos; y su uso para tratar trastornos, enfermedades y afecciones seleccionadas de asma, broncoconstri
CL2007003755A1 (es)	2008-08-22	Compuestos derivados de indol; composicion farmaceutica que comprende a dichos compuestos; y su uso en el tratamiento de afecciones o trastornos mediados por receptores s1p1 tales como enfermedades autoinmunitarias, asma, neuropatias, artritis, diabe
CL2008000738A1 (es)	2008-09-22	Compuestos derivados de malonamida; proceso para la preparacion de dichos compuestos; composicion farmaceutica que comprende a dichos compuestos; y su uso para el tratamiento de la depresion, enfermedad de parkinson y alzheimer, entre otras enfermeda
CL2007003804A1 (es)	2008-08-22	Compuestos derivados de indazol; procedimiento de preparacion; composicion farmaceutica que comprende a dichos compuestos; y su uso para tratar condiciones inflamatorias, tales como asma, epoc.
CL2008000060A1 (es)	2008-07-18	Compuestos derivados de 1-carboxi-2-amida pirrolidina; composicion farmaceutica que comprende a dichos compuestos; y su uso para tratar fibrosis quistica, carcinoma pulmonar, bronquitis cronica, enfermedad pulmonar obstructiva cronica, asma o una inf
CL2007002752A1 (es)	2008-07-11	Compuestos derivados de 3-(4-oxo-4h-quinazolin-3-il)-piperidina-2,6-diona; composicion farmaceutica que comprende a dichos compuestos; y su uso para tratar o prevenir enfermedades tales como cancer, dolor, degeneracion macular, trastorno pulmonar, tr
CL2008000703A1 (es)	2008-09-26	Compuestos derivados de pirimidinas sustituidas; procedimiento para la preparacion de dichos compuestos; composicion farmaceutica que comprende a dichos compuestos; y su uso para tratar transtornos hematologicos.
CL2007001976A1 (es)	2008-05-16	Compuestos derivados de dioxoalcanos y dioxoalquenos; procedimiento de preparacion; composicion farmaceutica; y su uso para tratar asma, tos, purito, hipersensibilidad.
UY31526A1 (es)	2009-08-03	4-(4-ciano-2-tioaril)dihidropirimidinonas y su uso
CL2007003797A1 (es)	2008-07-18	Compuestos derivados de pirrolo piridina; composicion farmaceutica que comprende a dichos compuestos; y su uso para el tratamiento de la enfermedad de alzheimer, parkinson, cancer, entre otras enfermedades.
CR9360A (es)	2008-08-26	Composiciones de herbicidas que contienen limoneno, formulaciones de concentrados de herbicidas y metodos para fabricar y usar las mismas.
CL2007002446A1 (es)	2008-04-04	Compuestos derivados de morfolino pirimidina; composicion farmaceutica; y su uso para preparar un medicamento para producir un efecto antiproliferante.
CL2007002099A1 (es)	2008-02-22	Compuestos derivados de 3h-espiro(1-benzofuran-2,4'-piperidina); proceso de preparacion; compuestos intermediarios; composicion farmaceutica; y uso para el tratamiento de enfermedades respiratorias, tales como epoc y asma.
CL2007003820A1 (es)	2008-08-01	Compuestos derivados de isoquinolinona sustituidos con cicloalquilamina; composicion farmaceutica que comprende a dichos compuestos; y su uso para tratar y/o prevenir hipertension, retinopatia, glaucoma, fibrosis pulmonar, alzheimer, sida, entre otra
CL2013001604A1 (es)	2014-07-25	Compuestos derivados de pirimidinona sustituida; composicion farmaceutica que los comprende; su uso para tratar la enfermedad de alzheimer y la aterosclerosis.
CL2008000829A1 (es)	2008-09-26	Compuestos derivados de 1h-indolo-7-carboxamida, inhibidores de ikk2; composicion farmaceutica que comprende a dichos compuestos; y su uso para tratar la artritis reumatoide, asma, rinitis o enfermedad pulmonar obstructiva cronica.
CL2008001393A1 (es)	2009-05-22	Compuestos derivados de dihidroquinonas y dihidronaftiridinas, inhibidores de jnk; composicion farmaceutica que comprende a dichos compuestos; y su uso para tratar artritis reumatoide, asma, diabetes tipo 2, alzheimer, enfermedad de parkinson, hiperproliferacion celular.
CL2008000596A1 (es)	2008-09-05	Forma de dosificacion que comprende 1-(6-[(3-ciclobutil-2,3,4,5-tetrahidro-1h-3-benzazepin-7-il)oxi]-3-piridinil)-2-pirrolidinona, un estabilizador, un excipiente; procedimiento de preparacion; y su uso para tratar enfermedades neurologicas.
WO2008145747A3 (en)	2009-02-12	Skin moisturizer and use thereof
BRPI0822066A2 (pt)	2015-09-22	derivados diolatos daizênio, o respectivo processo de preparo e as composições farmacêuticas que os contêm
CL2008000047A1 (es)	2008-07-18	Compuestos derivados de sulfonamida; procedimiento de preparacion; composicion farmaceutica que contiene a dichos compuestos; y su uso en el tratamiento y profilaxis de aterotrombosis y asma.
CL2008000088A1 (es)	2008-09-22	Compuestos derivados de 2,4-dioxo-pirimidina condensada; su proceso de preparacion; composicion farmaceutica que comprende a dichos compuestos; combinacion farmaceutica que comprende a dichos compuestos; y su uso para tratar un estado de enfermedad m
CL2007002251A1 (es)	2008-02-22	Compuestos derivados de amida; composicion farmaceutica que comprende a dicho compuesto; y uso del compuesto para el tratamiento de enfermedades asociadas con la miosina del musculo liso como hipertension, asma, glaucoma, enfermedad pulmonar, inconti